摘要:
The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 94 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.
摘要:
The invention relates to substantially pure interleukin 9 receptor molecules and the use thereof. The uses include use as an interleukin-9 inhibitor, as a diagnostic agent for determining interleukin-9, and as a screening agent for pharmaceuticals. The interleukin-9 receptor is characterized as a glycoprotein of about 64 kilodaltons which, upon digestion with N-glycosidase F, yields a peptide of about 54 kilodaltons.
摘要:
The invention describes HERV-AVL3-B tumor associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a HERV-AVL3-B gene product.
摘要:
A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
摘要:
Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.
摘要:
The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or ‘TRAP”, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要:
The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
摘要:
The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
摘要:
This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, β2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
摘要:
Peptides which satisfy the formula of SEQ ID NO: 10 bind to HLA-Cw*1601 molecules, and stimulate proliferation of cytolytic T cells. Examples of such peptides are those set forth in SEQ ID NOS: 4 and 5.
摘要翻译:满足SEQ ID NO:10的式的肽与HLA-Cw * 1601分子结合,并刺激溶细胞T细胞的增殖。 这些肽的实例是SEQ ID NO:4和5所示的那些。